GRFS vs PRQR
Grifols SA and ProQR Therapeutics N.v., side by side — 4 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | GRFS | PRQR |
|---|---|---|
| Revenue | €7.2B | €15.9M |
| Net income | €156.9M | €-42.2M |
| Gross margin | 38.7% | · |
| Net margin | 3.0% | −265.2% |
| Return on equity | 2.8% | −61.2% |
| Diluted EPS | €0.23 | −€0.40 |
| Dividend / share | · | · |
| Payout ratio | 0.6% | · |
| Free cash flow | €669.6M | €-53.8M |
| Equity | €5.9B | €49.4M |
| Net debt / equity | · | −1.77× |
| Current ratio | 2.66× | 3.09× |
| Revenue CAGR 5y | 7.2% | · |
| Profit CAGR 5y | −24.2% | · |
GRFS bills 453.4× the revenue of PRQR, and PRQR closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
4 years side by side
| Fiscal year | GRFS | PRQR |
|---|---|---|
| FY2024 | €7.2B | €18.9M |
| FY2023 | €6.6B | €6.5M |
| FY2022 | €6.1B | €3.6M |
| FY2021 | €4.9B | €1.3M |
Bottom line
| Fiscal year | GRFS | PRQR |
|---|---|---|
| FY2024 | €156.9M | €-27.8M |
| FY2023 | €42.3M | €-28.1M |
| FY2022 | €185.0M | €-64.4M |
| FY2021 | €188.7M | €-60.7M |
Standard deviation, each side
PRQR's return on equity has been more volatile than GRFS's over the 10 comparable fiscal years — 17.8 percentage points of standard deviation against 6.4.
10 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
GRFS led in return on equity in every one of the 10 comparable fiscal years — a structural lead, not a recent swing.
10 of 11 comparable fiscal years — a year missing data on either side is not counted.